Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19325381 | 0.75 | F2RL3 (0.57) | F2RL3 | |
| SCHEMBL6558073 | 0.69 | SPHK2 (0.46) | RAB9AHSP90AA1 | |
| SCHEMBL218318 | 0.64 | NR4A2 (0.36) | SMN1; SMN2NPC1PKMRAB9AMAPT | |
| SCHEMBL167744 | 0.61 | — | — | |
| SCHEMBL4539976 | 0.61 | RAB9A (0.49) | RAB9AHSP90AA1 | |
| SCHEMBL28154527 | 0.60 | PDPK1 (0.56) | RAB9AHSP90AA1 | |
| Hydrochloric Acid SCHEMBL10781780 | 0.60 | — | — | |
| SCHEMBL14843173 | 0.59 | PDE10A (0.52) | PDE10A | |
| SCHEMBL102331 | 0.58 | PDPK1 (0.59) | RAB9AHSP90AA1 | |
| SCHEMBL18641363 | 0.58 | SRC (0.38) | RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963466-B2 | Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists | VANDERBILT UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170253617-A1 | Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists | VANDERBILT UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253617-A1 | Substituted 5-Membered Heterocyclic Analogs as Protease Activated Receptor 4 (PAR-4) Antagonists | F2RL3, F2R, F2RL1 | TP53 1679/4885SMN1; SMN2 4473/4885NPC1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.